U.S. Stocks Rise with Dow Jones Surging Over 200 Points
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 24 2025
0mins
Source: Benzinga
- Dow Jones Surge: The Dow Jones index rose over 200 points on Wednesday, increasing by 0.48% to close at 48,673.55, indicating improved investor sentiment that could drive further market gains.
- Jobless Claims Decline: Initial jobless claims in the U.S. fell by 10,000 to 214,000 for the week ending December 20, below market estimates of 223,000, suggesting ongoing labor market improvement that supports economic recovery.
- Strong Stock Performance: Edgewise Therapeutics (NASDAQ:EWTX) shares surged 21% to $26.36 following positive updates from its ongoing CIRRUS-HCM Phase 2 trial, highlighting the company's potential in the biopharmaceutical sector.
- Diverse Company Growth: Multi Ways Holdings (NYSE:MWG) saw its stock price jump 62% to $0.41 after reporting a year-over-year increase in H1 EPS, reflecting strong growth momentum in its business operations.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CTXR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CTXR
About CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products, with a pipeline of anti-infectives in oncology, adjunct cancer care, stem cell therapy and prescription products. The Company's FDA approved LYMPHIR candidate is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline also includes Mino-Lok, and CITI-002 (Halo-Lido). Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs). Halo-Lido is a topical formulation of halobetasol propionate, a corticosteroid, and lidocaine that is intended for the treatment of hemorrhoids. The Company is also seeking to develop and commercialize the NoveCite mesenchymal stem cells (NC-iMSCs) to treat acute respiratory conditions with a near term focus on ARDS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UiPath to Join S&P Midcap 400 Index Effective January 2, 2026
- Market Focus: UiPath Inc. announced it will join the S&P Midcap 400 Index on January 2, 2026, replacing Synovus Financial Corp., a move expected to enhance the company's visibility and investor confidence.
- Stock Price Surge: Following this announcement, UiPath shares rose 6.8% to $17.05 in after-hours trading, reflecting market optimism regarding its future performance.
- FDA Approval: Agios Pharmaceuticals' AQVESME™ (mitapivat) received FDA approval for treating anemia in adults with alpha- or beta-thalassemia, although its stock fell 1.4%, this approval could pave the way for future sales growth.
- Stock Buyback Plan: Ramaco Resources announced a $100 million stock repurchase plan, with shares jumping 7.1% in after-hours trading, indicating the company's confidence in its value and potentially attracting more investor interest.
Continue Reading
U.S. Stocks Rise with Dow Jones Surging Over 200 Points
- Dow Jones Surge: The Dow Jones index rose over 200 points on Wednesday, increasing by 0.48% to close at 48,673.55, indicating improved investor sentiment that could drive further market gains.
- Jobless Claims Decline: Initial jobless claims in the U.S. fell by 10,000 to 214,000 for the week ending December 20, below market estimates of 223,000, suggesting ongoing labor market improvement that supports economic recovery.
- Strong Stock Performance: Edgewise Therapeutics (NASDAQ:EWTX) shares surged 21% to $26.36 following positive updates from its ongoing CIRRUS-HCM Phase 2 trial, highlighting the company's potential in the biopharmaceutical sector.
- Diverse Company Growth: Multi Ways Holdings (NYSE:MWG) saw its stock price jump 62% to $0.41 after reporting a year-over-year increase in H1 EPS, reflecting strong growth momentum in its business operations.
Continue Reading